Aetna issued a revised clinical policy bulletin this month removing the requirement that patients complete or fail a standard six-week TMS course before authorizing accelerated protocols. The change makes Aetna the largest national payer to cover SAINT-style and other accelerated theta burst regimens as a first-line TMS option for treatment-resistant depression.
The previous policy created a paradox: patients well-suited to accelerated TMS — typically those with severe symptoms, high suicide risk, or inability to commit to six weeks of daily visits — were forced into the slower protocol first. Aetna's medical director cited the growing replication data, including the multi-site SAINT study published earlier this month, as the basis for the change.
Coverage applies to FDA-cleared theta burst devices delivered in network-credentialed clinics. Prior authorization is still required, and the policy specifies a maximum of 50 sessions across the five-day course, consistent with the published Stanford protocol.
Industry analysts expect United, Cigna, and several Blue Cross Blue Shield plans to follow within six to twelve months. Coverage parity for accelerated protocols has been a persistent barrier for clinics offering them, since out-of-pocket costs frequently exceeded $25,000 without insurance.
Source
Reporting based on coverage from Aetna Clinical Policy Bulletin. This article is editorial summary intended for general information; it is not medical advice.